MK-677 (ibutamoren) is an orally active, non-peptide growth hormone secretagogue that reached late-stage human trials but was never approved as a medicine. This page describes trial findings, not established treatments.
What the trials actually showed
MK-677's documented benefits in humans are narrower than its marketing but more solid than most compounds sold beside it: randomized trials showed it reliably raises growth hormone and IGF-1 to young-adult levels, adds a modest amount of fat-free mass (about 1.1 kg over a year in older adults), reverses the muscle-protein loss of a calorie-restricted diet, and improves some sleep and bone-turnover measures. What no trial ever showed is the outcome people usually buy it for — better strength, function, fat loss, or aging — and two clinical programs ended in a negative result or an early stop for safety.
Growth hormone and IGF-1
This is the best-documented effect. In 32 healthy adults aged 64–81, two weeks of oral MK-677 raised mean 24-hour GH concentrations dose-dependently — roughly +97% at 25 mg daily — and four weeks lifted IGF-1 from 141 µg/L to 265 µg/L, into the range of healthy young adults (J Clin Endocrinol Metab 1996). The landmark study is Nass et al.: a 2-year, double-blind trial in 65 healthy older adults in which 25 mg daily restored GH and IGF-1 to young-adult levels for the full dosing period (Ann Intern Med 2008).
Two caveats travel with this finding. The elevation preserved GH's natural pulsatile pattern — a real mechanistic point in its favor — but the same trials recorded rising fasting glucose and falling insulin sensitivity at the same doses. The hormone effect and the metabolic cost have never been separated.
Muscle, catabolism, and body composition
Body-composition results are real but modest:
In the 2-year older-adult trial, fat-free mass increased 1.1 kg with MK-677 versus a 0.5 kg decrease on placebo at 12 months — with no significant change in visceral or total fat, and no improvement in strength or function (Ann Intern Med 2008).
In 24 obese men treated for 8 weeks, IGF-1 rose about 40% and fat-free mass increased, but total and visceral fat did not change — the "oral GH for fat loss" narrative did not survive contact with a placebo group (J Clin Endocrinol Metab 1998).
The clearest anabolic signal is anti-catabolic: in 8 healthy volunteers on a strict calorie-restricted diet, one week of 25 mg daily flipped nitrogen balance from −1.48 to +0.31 g/day — evidence it can protect muscle protein during an energy deficit, at least short-term (J Clin Endocrinol Metab 1998).
Appetite stimulation — a direct ghrelin-receptor effect — cuts both ways: a potential benefit in wasting contexts, an unwanted side effect for most other users.
Sleep and bone findings
Two smaller literatures round out the benefit claims. In a polysomnography study, prolonged MK-677 treatment improved objective sleep-quality measures, including a nearly 50% increase in REM sleep in older subjects (Neuroendocrinology 1997). And in 187 elderly adults across three placebo-controlled studies, MK-677 increased biochemical markers of both bone formation and bone resorption (J Bone Miner Res 1999). Note what that is: higher bone turnover, not demonstrated fracture prevention or bone-density gain — a distinction the marketing routinely skips.
The benefits that did not materialize
MK-677 is the rare gray-market compound whose big claims were actually put to the test — and the tests came back negative. A 563-patient, 12-month randomized trial in Alzheimer's disease found no effect on any cognitive or functional endpoint despite a 72.9% rise in IGF-1 (Neurology 2008). A hip-fracture recovery trial in 123 elderly patients was stopped early for a heart-failure safety signal before functional benefit could be shown (Arch Gerontol Geriatr 2011).
The honest summary: MK-677 demonstrably restores a youthful hormone profile, and that restoration has never been shown to deliver a meaningful clinical benefit in any studied population. See the side-effect profile for the other half of the ledger.